List of Excipients in Branded Drug CIPROFLOXACIN OTIC

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Xspire Pharma Llc	CIPROFLOXACIN OTIC	ciprofloxacin	42195-550	GLYCERIN
Xspire Pharma Llc	CIPROFLOXACIN OTIC	ciprofloxacin	42195-550	POVIDONE
Xspire Pharma Llc	CIPROFLOXACIN OTIC	ciprofloxacin	42195-550	WATER

Generic Drugs Containing CIPROFLOXACIN OTIC

Company	Ingredient	NDC	Excipient
Genus Lifesciences	ciprofloxacin	64950-381	GLYCERIN
Genus Lifesciences	ciprofloxacin	64950-381	LACTIC ACID
Genus Lifesciences	ciprofloxacin	64950-381	POVIDONE

What are the Most Frequently-Used Excipients in CIPROFLOXACIN OTIC?

# Of NDCs	Excipient
1	GLYCERIN
1	LACTIC ACID
1	POVIDONE

Last updated: August 19, 2026

Executive summary: Ciprofloxacin otic is a mature, low-cost antibiotic market with limited composition-of-matter protection and meaningful commercial opportunities in formulation, delivery, preservation, and pediatric convenience. The principal U.S. products are Ciprodex, a ciprofloxacin/dexamethasone suspension; Cetraxal, a ciprofloxacin solution; and Otiprio, a single-dose ciprofloxacin suspension. Generic competition has reduced the value of basic ciprofloxacin otic solution, while preservative-free unit doses, operating-room administration, improved residence time, and differentiated excipient systems retain commercial potential.

Ciprofloxacin Otic Excipient Strategy and Commercial Opportunities

What ciprofloxacin otic products are marketed in the United States?

Ciprofloxacin otic products use either ciprofloxacin hydrochloride or ciprofloxacin as the active antibacterial component. Commercial products differ primarily by concentration, dosage form, corticosteroid inclusion, container system, and administration setting.

Product	Active ingredients	Dosage form	U.S. regulatory status	Primary use
Ciprodex	Ciprofloxacin 0.3% and dexamethasone 0.1%	Sterile otic suspension	NDA 021537; approved 2003	Acute otitis media with tympanostomy tubes and acute otitis externa
Cetraxal	Ciprofloxacin 0.2%	Sterile otic solution	NDA 022750; approved 2010	Acute otitis externa
Otiprio	Ciprofloxacin 0.6%	Sterile otic suspension	NDA 207311; approved 2015	Pediatric otitis media with tympanostomy tubes
Generic ciprofloxacin otic solution	Ciprofloxacin, generally 0.2%	Sterile otic solution	ANDA products	Acute otitis externa
Generic ciprofloxacin/dexamethasone otic suspension	Ciprofloxacin 0.3% and dexamethasone 0.1%	Sterile otic suspension	ANDA products	Otitis externa and tympanostomy-tube otorrhea

Ciprodex combines antibacterial and anti-inflammatory treatment. Cetraxal competes on a simpler, lower-cost solution platform. Otiprio uses a higher ciprofloxacin concentration and single-dose administration for procedural use. FDA product labeling identifies the approved indications, concentrations, excipients, and administration instructions for each product.[1-3]

What excipients are used in ciprofloxacin otic products?

Excipients in ciprofloxacin otic products must support chemical stability, suspension or solution performance, sterility, local tolerability, and reliable delivery into the ear canal or middle ear.

Ciprodex excipient system

Ciprodex contains a suspension system that includes benzalkonium chloride, acetic acid, sodium acetate, mannitol, edetate disodium, hydrochloric acid or sodium hydroxide for pH adjustment, and purified water.[1]

The formulation strategy has several functions:

• Acetic acid and sodium acetate provide buffering.
• Mannitol contributes to tonicity and suspension properties.
• Edetate disodium can bind trace metals that promote degradation.
• Benzalkonium chloride provides preservative activity in a multidose container.
• The suspension vehicle keeps dexamethasone and ciprofloxacin adequately dispersed.

The main commercial limitation is that benzalkonium chloride can create tolerability and labeling concerns in sensitive pediatric or chronically treated patients. A preservative-free version using a unit-dose container could be differentiated, but it would require a new stability, sterility, extractables, and packaging program.

Cetraxal excipient system

Cetraxal is a sterile ciprofloxacin solution supplied in single-dose containers. Its inactive ingredients include glycerin and povidone, with water and pH-adjusting agents used to achieve the labeled formulation.[2]

The solution format avoids the redispersion and dose-uniformity issues associated with suspensions. Glycerin can contribute to tonicity and viscosity. Povidone can improve wetting and solution behavior, although its molecular weight and concentration must be controlled to avoid excessive viscosity or residue.

The single-dose format removes the need for a multidose preservative system. That approach is attractive for pediatric use and repeated clinic dispensing, but it increases packaging cost and can reduce supply-chain efficiency.

Otiprio excipient system

Otiprio is a 0.6% ciprofloxacin otic suspension supplied as a single-dose product. The inactive ingredients include polysorbate 20, povidone, sodium chloride, water for injection, and pH-adjusting agents.[3]

Its formulation is designed for administration by a healthcare professional during tympanostomy-tube surgery. The higher drug concentration and suspension vehicle support a small administration volume and prolonged local exposure relative to conventional drops.

The product illustrates a central excipient opportunity: excipients can create commercial value by supporting a new delivery setting rather than by changing ciprofloxacin’s antibacterial mechanism.

Which excipient strategies offer the strongest commercial opportunity?

The strongest opportunities are in preservative-free delivery, residence-time enhancement, suspension control, and packaging-linked differentiation.

Preservative-free unit-dose formulations

Preservative-free ciprofloxacin otic products can target:

• Infants and young children.
• Patients with tympanostomy tubes.
• Repeated treatment courses.
• Patients with sensitivity to benzalkonium chloride.
• Surgical and outpatient procedural settings.

A unit-dose system can use a solution, suspension, or in situ gelling vehicle. Commercial success depends on reducing administration complexity without creating excessive cost or waste.

Mucoadhesive and residence-time systems

Otic formulations are vulnerable to drainage from the ear canal. Poloxamers, cellulose derivatives, carbomers, hyaluronic acid derivatives, and selected polyvinylpyrrolidone grades can increase residence time.

The principal development risks are:

• Excessive viscosity that impairs administration.
• Interference with tympanostomy-tube patency.
• Delayed clearance from the middle ear.
• Local irritation or impaired hearing from residual vehicle.
• Difficult sterile filtration or aseptic processing.
• Inconsistent drug release from a gel or structured suspension.

A successful formulation must show longer local retention without materially increasing pain, fullness, hearing impairment, or administration force.

Improved suspension architecture

Suspension products create opportunities in:

• Particle-size distribution.
• Crystal habit and polymorph control.
• Sedimentation rate.
• Redispersibility.
• Dose uniformity.
• Delivery through narrow dropper tips.
• Reduced shaking requirements.

A suspension that remains uniform after storage and delivers a consistent dose after limited shaking can support a product claim based on convenience and reliability. Such claims require comparative performance data and may support a 505(b)(2) strategy when the product differs materially from an established reference.

Low-volume and concentrated formulations

A higher-concentration formulation can reduce the number of drops and improve adherence. Otiprio demonstrates the value of this approach in a procedural setting.[3]

The development challenge is local exposure. Ciprofloxacin is generally well tolerated otically, but concentrated formulations require evaluation of:

• Local irritation.
• Cochlear and vestibular safety.
• Middle-ear exposure.
• Tissue retention.
• Effect on tube function.
• Dose volume and administration accuracy.

Alternative preservative systems

Multidose products may require antimicrobial preservation unless the container and use pattern qualify for a preservative-free design. Potential alternatives include phenoxyethanol, parabens, sorbates, and organic-acid systems, but substitution is not straightforward.

The preservative must remain effective across the formulation’s pH range and must not reduce ciprofloxacin potency, alter suspension behavior, or increase otic irritation. For pediatric otic products, a preservative-free unit-dose strategy is generally more commercially defensible than replacing benzalkonium chloride with another preservative.

What patents protect ciprofloxacin otic products?

Ciprofloxacin’s core composition-of-matter patent estate is expired in the United States. Commercial protection therefore depends on product-specific formulation, dosage-form, manufacturing, container, and method-of-use patents.

Protection category	Current commercial importance
Ciprofloxacin composition of matter	Expired; no meaningful barrier to generic ciprofloxacin
Ciprofloxacin otic solution	Weak to moderate; basic formulations are vulnerable to ANDA competition
Ciprofloxacin/dexamethasone suspension	Product-specific formulation and dosage-form claims may have delayed generic entry, but the market now includes generic competition
Single-dose ciprofloxacin suspension	Potentially stronger where claims cover concentration, particle engineering, vehicle, or administration method
In situ gel or mucoadhesive formulation	Potentially strong if claims cover defined excipient ranges and clinically relevant retention
Sterile manufacturing process	Useful as a secondary barrier, but difficult to enforce against independently developed processes
Container and delivery system	Commercially relevant where the device is integral to dose accuracy or sterility

The FDA Orange Book is the primary source for patents and regulatory exclusivity listed against approved drug products.[4] Patent numbers, expiration dates, and listed products should be reviewed at the specific NDA or reference-listed-drug level because patents may attach to the combination product rather than to ciprofloxacin alone.

When does ciprofloxacin otic lose exclusivity?

Ciprofloxacin otic has no remaining new chemical entity exclusivity. The relevant barriers are product-specific patents, pediatric exclusivity, regulatory exclusivity, and approval timing.

Product	Key FDA milestone	Exclusivity assessment
Ciprodex	Approved 2003	Original regulatory exclusivity expired; product-specific patent protection has been substantially eroded
Cetraxal	Approved 2010	Original regulatory exclusivity expired; basic solution technology is exposed to generic competition
Otiprio	Approved 2015	Original regulatory exclusivity expired; commercial protection depends on remaining patents, supply, and clinical positioning

For generic applicants, Paragraph IV certifications are relevant where an Orange Book patent remains listed. A Paragraph IV filing alleges that the listed patent is invalid, unenforceable, or will not be infringed. The reference-product sponsor may file patent litigation within 45 days, triggering a statutory stay of approval of up to 30 months under the Hatch-Waxman framework.[5]

Which companies are challenging ciprofloxacin otic products?

Generic manufacturers have challenged the principal ciprofloxacin otic platforms through ANDA development. The competitive field includes established generic companies and specialty ophthalmic and otic manufacturers. The principal competitive assets are:

• Generic ciprofloxacin otic solution.
• Generic ciprofloxacin/dexamethasone otic suspension.
• Alternative branded or authorized-generic supply.
• Hospital and clinic contracts for procedural products.
• Retail pharmacy distribution for acute otitis externa.

A company entering the market with a basic ciprofloxacin solution faces limited differentiation and price pressure. A product with unit-dose packaging, preservative-free positioning, or superior retention has a more defensible commercial profile.

What is the FDA regulatory status of ciprofloxacin otic products?

Ciprofloxacin otic products are prescription drugs approved through NDAs or ANDAs. The regulatory pathway depends on the proposed product.

ANDA pathway

An ANDA is most appropriate for a product that matches the reference-listed drug in active ingredients, dosage form, strength, route, labeling, and key quality attributes. This pathway is commercially efficient for:

• Ciprofloxacin otic solution.
• Ciprofloxacin/dexamethasone otic suspension.
• Conventional multidose or single-dose products that closely match an approved reference.

The ANDA route does not provide broad protection for a new excipient system or a materially different delivery mechanism.

505(b)(2) pathway

A 505(b)(2) application may be appropriate for:

• A new vehicle.
• A new concentration.
• A sustained-residence formulation.
• A different container or administration device.
• A new dosing regimen.
• A single-dose product with clinical advantages not captured by an ANDA.

The sponsor must establish safety and effectiveness for the proposed product and address listed patents and exclusivity associated with the relied-upon reference product.[6]

What patent litigation and settlement risks affect ciprofloxacin otic?

The principal litigation risk is concentrated in combination suspensions and differentiated single-dose products. A generic solution generally has lower patent risk because the technology is mature and the dosage form is simple.

Potential disputes involve:

• Suspension particle-size limitations.
• Defined polymer or surfactant ranges.
• Drug-release or residence-time claims.
• Combination claims covering ciprofloxacin and dexamethasone.
• Method-of-use claims for tympanostomy-tube patients.
• Container-closure systems.
• Manufacturing controls for sterile suspensions.

Settlement agreements may include licensed entry dates, authorized-generic arrangements, or restrictions on product launch. These agreements may be subject to Federal Trade Commission review and must be assessed against the listed patents, litigation docket, and FDA approval status. A commercial diligence review should distinguish a patent expiry date from the actual generic launch date because litigation, manufacturing readiness, FDA review, and supply contracts can produce different timing outcomes.

How does ciprofloxacin otic compare with competing antibiotic ear drops?

Product class	Advantages	Commercial weakness
Ciprofloxacin solution	Low manufacturing complexity; established safety; broad generic supply	Limited differentiation and price erosion
Ciprofloxacin/dexamethasone suspension	Antibacterial and anti-inflammatory activity; strong physician recognition	Generic competition; suspension manufacturing complexity
Single-dose ciprofloxacin suspension	Convenient administration; preservative-free potential; procedural use	Higher unit cost; dependence on surgery and clinic channels
Ofloxacin otic solution	Established generic alternative; simple formulation	Limited differentiation
Aminoglycoside-containing drops	Low cost and established use	Greater concern where tympanic membrane integrity is uncertain
Fluoroquinolone-steroid combinations	Clinical convenience in inflammatory infections	Combination-product patent and generic substitution pressure

Ciprofloxacin remains commercially attractive where the product provides a clear delivery or adherence benefit. It is less attractive as an undifferentiated multidose solution.

What generic launch scenarios exist for ciprofloxacin otic?

Scenario 1: Basic solution entry

This is the highest-probability and lowest-value scenario. Multiple manufacturers can supply a conventional ciprofloxacin solution, producing pharmacy substitution and rapid price compression.

Scenario 2: Combination-suspension entry

Generic ciprofloxacin/dexamethasone suspension can take share from Ciprodex through formulary substitution and payer pressure. The main barriers are suspension equivalence, device compatibility, sterile manufacturing, and patent certification.

Scenario 3: Differentiated single-dose entry

A single-dose suspension or concentrated product can compete for procedural and pediatric use. Entry is more difficult because the applicant may need a 505(b)(2) application, new clinical or pharmacokinetic support, and a defensible device or formulation package.

Scenario 4: Reformulated premium product

A preservative-free, low-volume, residence-enhancing product can command a premium if it demonstrates measurable adherence, administration, or tolerability benefits. Without clinical differentiation, payers may treat it as interchangeable with lower-cost generics.

How strong is the ciprofloxacin otic patent estate?

The estate is weak for ciprofloxacin itself and moderate for differentiated formulations.

A practical strength assessment is:

Asset	Patent strength	Market protection
Conventional ciprofloxacin solution	Low	Rapid generic substitution
Conventional ciprofloxacin/dexamethasone suspension	Low to moderate	Generic competition with possible formulation disputes
Preservative-free unit-dose solution	Moderate	Packaging and formulation claims can delay direct copying
High-concentration suspension	Moderate	Concentration, particle, and dosing claims may support differentiation
Mucoadhesive or in situ gel	Moderate to high	Stronger if claims cover composition and measured retention
Proprietary delivery device	Moderate	Protection depends on whether the device is necessary for dose delivery

Patent value is highest when the claims cover a specific excipient combination tied to a measurable performance result. Broad claims to generic polymers, surfactants, or buffers are more vulnerable to invalidity and design-around activity.

What manufacturing and intellectual-property barriers matter?

Sterile otic suspensions are more difficult to manufacture than simple solutions. Key barriers include:

• Sterile processing and aseptic filling.
• Control of ciprofloxacin particle size.
• Prevention of sedimentation and caking.
• Consistent redispersion.
• Compatibility with low-volume droppers.
• Container-closure integrity.
• Extractables and leachables.
• Microbial control during filling and use.
• Stability under shipping and temperature excursions.

The strongest manufacturing moat is usually process knowledge rather than a single patent. A formulation may be legally easy to copy but operationally difficult to reproduce at commercial scale.

What licensing deals and commercial partnerships are relevant?

Ciprofloxacin otic products are mature assets, so licensing value depends on differentiated delivery rather than on ciprofloxacin access. Attractive deal structures include:

• Regional commercialization rights for pediatric otic products.
• Hospital-channel rights for procedural single-dose products.
• Co-development of preservative-free formulations.
• Supply agreements for sterile suspension manufacture.
• Device partnerships for calibrated otic delivery.
• Authorized-generic arrangements linked to branded products.

The most valuable partner is likely to be a company with established otolaryngology, pediatric, ambulatory-surgery, or hospital distribution. A conventional generic solution is more likely to be supplied through manufacturing and distribution contracts than through a high-value licensing transaction.

Is there biosimilar risk for ciprofloxacin otic?

No. Ciprofloxacin is a small-molecule antibiotic, not a biologic. Biosimilar regulation does not apply. Competitive risk arises from generic drugs approved under the ANDA pathway and, for materially modified products, 505(b)(2) applications.

What revenue exposure does ciprofloxacin otic create?

Revenue exposure is highest for branded products that depend on price premiums over generic ciprofloxacin. The main erosion mechanisms are:

• Generic substitution.
• Payer formulary exclusion.
• Retail price compression.
• Hospital purchasing contracts.
• Reduced differentiation between solution and suspension products.
• Physician switching from combination products to separate low-cost therapies.

Revenue resilience improves when the product has:

• A protected or difficult-to-copy excipient system.
• A single-dose or procedure-linked administration model.
• Strong pediatric positioning.
• A device or packaging advantage.
• Contracted hospital or surgery-center demand.
• Evidence supporting reduced treatment burden.

Key Takeaways

• Ciprofloxacin otic is a mature small-molecule market with no biosimilar risk and limited composition-of-matter protection.
• Basic ciprofloxacin otic solution is commercially vulnerable to generic competition.
• Ciprodex, Cetraxal, and Otiprio represent distinct formulation and channel strategies.
• The strongest excipient opportunities are preservative-free unit doses, residence-enhancing vehicles, concentrated suspensions, and improved redispersion systems.
• Product-specific patents can protect formulations, manufacturing methods, and delivery systems after ciprofloxacin’s core patents expire.
• An ANDA is suitable for close copies; materially differentiated formulations may require a 505(b)(2) application.
• Commercial value is highest in pediatric, procedural, hospital, and otolaryngology channels.
• A successful premium product must show a measurable administration, adherence, safety, or residence-time benefit.

FAQs

Can ciprofloxacin otic be formulated without benzalkonium chloride?

Yes. A single-dose, preservative-free solution or suspension can eliminate the need for benzalkonium chloride, provided the sponsor validates sterility, container closure, stability, and in-use handling.

Which excipient is best for prolonging ciprofloxacin retention in the ear?

No single excipient is universally optimal. Polymers such as poloxamers, carbomers, cellulose derivatives, and povidone can increase viscosity or adhesion, but the selected system must preserve drug release, tube patency, sterility, and local tolerability.

Is a ciprofloxacin otic gel automatically eligible for generic approval?

No. A gel with a materially different vehicle, concentration, release profile, or administration method may require a 505(b)(2) application rather than an ANDA.

Can an otic formulation patent block generic ciprofloxacin solution?

Usually not if the generic product does not practice the patent claims. A formulation patent may block copying of the claimed vehicle or suspension system while leaving conventional solution products free to enter.

What is the most defensible commercial position for a new ciprofloxacin otic product?

A preservative-free, low-volume, pediatric or procedure-linked product with validated residence-time, dosing, or administration advantages has the strongest position. A conventional multidose solution has the weakest commercial defensibility.

References

1. U.S. Food and Drug Administration. (2023). Ciprodex (ciprofloxacin and dexamethasone) otic suspension prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Cetraxal (ciprofloxacin otic solution) prescribing information. FDA.

3. U.S. Food and Drug Administration. (2023). Otiprio (ciprofloxacin otic suspension) prescribing information. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.

6. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). FDA.